2-[2-[2-[(4-Chlorophenyl)methyl]-6-methyl-9-[(5-phenylpyridin-2-yl)methoxy]-5-thia-2-azatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraen-3-yl]ethenyl]benzonitrile | 170243-08-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-[2-[2-[(4-Chlorophenyl)methyl]-6-methyl-9-[(5-phenylpyridin-2-yl)methoxy]-5-thia-2-azatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraen-3-yl]ethenyl]benzonitrile
• CAS: 170243-08-0
• 化学式: C₃₉H₃₀ClN₃OS
• 分子量: 624.206
• InChiKey: ZKMAHKGQKYYLMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  45
• 可旋转键数：
  8
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  76.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[2-[2-[(4-Chlorophenyl)methyl]-6-methyl-9-[(5-phenylpyridin-2-yl)methoxy]-5-thia-2-azatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraen-3-yl]ethenyl]benzonitrile 在 三乙基硅烷 、 氢氧化钾 、 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 反应 16.25h， 生成 2-<2-<1-(4-chlorobenzyl)-4-methyl-6-<(5-phenylpyridin-2-yl)methoxy>-4,5-dihydro-1H-thiopyrano<2,3,4-c,d>indol-2-yl>ethyl>benzoic acid
  参考文献：
  名称：

  Thiopyranol[2,3,4-c,d]indoles as Inhibitors of 5-Lipoxygenase, 5-Lipoxygenase-Activating Protein, and Leukotriene C4 Synthase

  摘要：

  The attachment of an arylacetic or benzoic acid moiety to the thiopyrano[2,3,4-c,d]indole nucleus results in compounds which are highly potent and selective 5-lipoxygenase (5-LO) inhibitors. These compounds are structurally simpler than previous compounds of similar potency in that they contain a single chiral center. From the data presented, 2-[[1-(3-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano [2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 14b, was shown to inhibit 5-hydroperoxyeicosatetraenoic acid (5-HPETE) production by human 5-LO (IC50 of 18 nM). The acid 14b is highly selective as an inhibitor of 5-LO activity when compared to the inhibition of ram seminal vesicle cyclooxygenase (IC50 > 5 mu M) or human leukocyte leukotriene A(4) (LTA(4)) hydrolase (IC50 > 20 mu M). In addition, 14b was inactive in a 5-lipoxygenase-activating protein (FLAP) binding assay at 10 mu M. In vivo studies showed that 14b is bioavailable in rat and functionally active in the hyperreactive rat model of antigen-induced dyspnea (74% inhibition at 0.5 mg/kg po; 2 h pretreatment). In the conscious squirrel monkey model of asthma, 14b showed excellent functional activity at 0.1 mg/kg against antigen-induced bronchoconstriction (94% inhibition of the increase in R(L) and 100% inhibition in the decrease in C-dyn; n = 4) Resolution of this compound gave (-)-14b, the most potent enantiomer (IC50 = 10 nM in the human 5-LO assay), which was shown to possess the S configuration at the chiral center by X-ray crystallographic analysis of an intermediate. Subsequent studies on the aryl thiopyrano[2,3,4-c,d]indole series of inhibitors led to the discovery of potent dual inhibitors of both FLAP and 5-LO, the most potent of which is 2-[[1-(4-chlorobenzyl)-4-methyl-6-(quinolin-2-ylmethoxy) -4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 19. Acid 19 has an IC50 of 100 nM for the inhibition of 5-HPETE production by human 5-LO and is active in a FLAP binding assay with an IC50 of 32 nM. Furthermore, thiopyrano[2,3,4-c,d]indoles such as 1 and 14b are capable of inhibiting the LTC(4) synthase reaction in a dose dependent manner (IC(50)s of 11 and 16 mu M, respectively, compared to that of LTC(2) at 1.2 mu M) in contrast to other, structurally distinct 5-LO inhibitors. It has also been observed that the thiopyrano[2,3,4-c,d]indole class of compounds strongly promotes the translocation of 5-LO from the cytosol to a membrane fraction in the presence or absence of the ionophore A23187. The membrane-bound 5-LO retains its activity, and this association with the membrane is not reversed with the FLAP inhibitor MK-886. These observations, in part, support the hypothesis that these compounds act by binding at the arachidonic acid-binding site on FLAP, 5-LO, and LTC(4) synthase and that the thiopyrano[2,3,4-c,d]indole is capable of mimicking an active conformation of arachidonic acid.

  DOI：

  10.1021/jm00022a020
• 作为产物：
  描述：

  2-氰基溴苄 在 双(三甲基硅烷基)氨基钾 作用下， 以 乙腈 为溶剂， 反应 88.75h， 生成 2-[2-[2-[(4-Chlorophenyl)methyl]-6-methyl-9-[(5-phenylpyridin-2-yl)methoxy]-5-thia-2-azatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraen-3-yl]ethenyl]benzonitrile
  参考文献：
  名称：

  Thiopyranol[2,3,4-c,d]indoles as Inhibitors of 5-Lipoxygenase, 5-Lipoxygenase-Activating Protein, and Leukotriene C4 Synthase

  摘要：

  The attachment of an arylacetic or benzoic acid moiety to the thiopyrano[2,3,4-c,d]indole nucleus results in compounds which are highly potent and selective 5-lipoxygenase (5-LO) inhibitors. These compounds are structurally simpler than previous compounds of similar potency in that they contain a single chiral center. From the data presented, 2-[[1-(3-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano [2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 14b, was shown to inhibit 5-hydroperoxyeicosatetraenoic acid (5-HPETE) production by human 5-LO (IC50 of 18 nM). The acid 14b is highly selective as an inhibitor of 5-LO activity when compared to the inhibition of ram seminal vesicle cyclooxygenase (IC50 > 5 mu M) or human leukocyte leukotriene A(4) (LTA(4)) hydrolase (IC50 > 20 mu M). In addition, 14b was inactive in a 5-lipoxygenase-activating protein (FLAP) binding assay at 10 mu M. In vivo studies showed that 14b is bioavailable in rat and functionally active in the hyperreactive rat model of antigen-induced dyspnea (74% inhibition at 0.5 mg/kg po; 2 h pretreatment). In the conscious squirrel monkey model of asthma, 14b showed excellent functional activity at 0.1 mg/kg against antigen-induced bronchoconstriction (94% inhibition of the increase in R(L) and 100% inhibition in the decrease in C-dyn; n = 4) Resolution of this compound gave (-)-14b, the most potent enantiomer (IC50 = 10 nM in the human 5-LO assay), which was shown to possess the S configuration at the chiral center by X-ray crystallographic analysis of an intermediate. Subsequent studies on the aryl thiopyrano[2,3,4-c,d]indole series of inhibitors led to the discovery of potent dual inhibitors of both FLAP and 5-LO, the most potent of which is 2-[[1-(4-chlorobenzyl)-4-methyl-6-(quinolin-2-ylmethoxy) -4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 19. Acid 19 has an IC50 of 100 nM for the inhibition of 5-HPETE production by human 5-LO and is active in a FLAP binding assay with an IC50 of 32 nM. Furthermore, thiopyrano[2,3,4-c,d]indoles such as 1 and 14b are capable of inhibiting the LTC(4) synthase reaction in a dose dependent manner (IC(50)s of 11 and 16 mu M, respectively, compared to that of LTC(2) at 1.2 mu M) in contrast to other, structurally distinct 5-LO inhibitors. It has also been observed that the thiopyrano[2,3,4-c,d]indole class of compounds strongly promotes the translocation of 5-LO from the cytosol to a membrane fraction in the presence or absence of the ionophore A23187. The membrane-bound 5-LO retains its activity, and this association with the membrane is not reversed with the FLAP inhibitor MK-886. These observations, in part, support the hypothesis that these compounds act by binding at the arachidonic acid-binding site on FLAP, 5-LO, and LTC(4) synthase and that the thiopyrano[2,3,4-c,d]indole is capable of mimicking an active conformation of arachidonic acid.

  DOI：

  10.1021/jm00022a020